Parma, March 31, 2016 – Chiesi Farmaceutici closed 2015 on a high note by reporting annual turnover of
€1.467 million, an increase of more than 9.4% over the previous year, and EBITDA equal to €407 million (a year-on-year increase of over 9%). The robust health of the company is mirrored in its investment in innovation and development, with R&D expenditure rising by over 28% in the 2014-2015 period, from €236m to €300m, or 20% of total sales. The Group currently has 41 active research and development projects.
Chiesi remains committed to the domestic market, and 2015 saw significant investment in Italy with €35m spent on expanding the state-of-the-art Curosurf production plant in Parma to meet demand for one of the group’s most successful products.
“In the latest chapter of a story that just turned 80 years old, we have once again demonstrated our commitment to excellence and our ability to achieve outstanding results, thanks to our agility and ability to both adapt to the dynamic circumstances which characterise our industry, and to be at the cutting-edge of development.
Chiesi’s expertise in the areas of Respiratory, Neonatology and Rare Diseases underpins our success, with our constantly expanding knowledge-base generating a wealth of fresh ideas that in turn lead to the development of innovative – and in many cases unique – medical solutions. Our aim is to continue to give hope to those patients who until now have no, or limited, therapeutic alternatives.
2016 will continue to see Chiesi adhering to its core aim of drug development through its own internal pre-clinical and clinical research programmes, but also seeking opportunities to acquire products which are an organic fit with our range of respiratory and special care solutions”.
Alberto Chiesi, President of Chiesi Farmaceutici S.p.A.
The respiratory drug market is one in which Chiesi is a key global player, and a number of brands in its portfolio are continuing to generate significant growth, and revenue.
Foster® (beclomethasone dipropionate and formoterol fumarate), a drug used to treat asthma and other respiratory disorders, achieved sales of €492 million in 2015, a 19.7% year-on-year increase.
Sales of Curosurf® (poractant alfa), a pulmonary surfactant, exceeded €200m, growing by 14.4% over 2014 and confirming its global importance as a potentially life-saving drug. It provides an effective treatment for respiratory distress syndrome (RDS), a disorder of premature newborns. Curosurf is increasing its share of not only the European market, but also that of the U.S. and Far East.
Sales of Clenil® (beclomethasone dipropionate), a drug designed to prevent asthma through a reduction of inflammation of the lungs, also grew, generating revenue of over €176m.
MARKETS AND COMMERCIAL OPERATIONS
Chiesi’s global presence is reflected by 80% of turnover in 2015 being generated by non-Italian sales. The Group’s excellent results were also in part attributable to Chiesi’s swift and smooth integration of the U.S. speciality pharmaceutical business Cornerstone Therapeutics, acquired little more than a year ago. Strong sales of two products developed by Chiesi’s own research division were complemented by drugs from Cornerstone’s portfolio, boosting turnover in 2015 by 16.9%, in US$.
In Europe, Chiesi affiliates showed solid growth, with an average increase in turnover of 5.2%. Similarly, despite the volatility in emerging markets and continuing economic uncertainties, the Group still achieved remarkable results in Brazil, Turkey, China, Pakistan and Mexico. Overall, sales grew by 11.7%, in local currencies.
PROSPECTS FOR 2016
2016 will see the submission of two new innovative products to the European Medicine Agency, both relating to Chiesi’s core therapeutic areas. In Respiratory, the first triple combination for patients with chronic obstructive pulmonary disease (COPD) will be submitted for approval. In the Rare Disease area, we plan to submit velmanase alfa (Lamazyn), a recombinant enzyme indicated for alpha-mannosidosis, an inherited condition which leads to a progressive deterioration of motor and mental functions.
In the words of Ugo Di Francesco, CEO of Chiesi Farmaceutici:
“Chiesi Group’s presence in the global pharmaceutical landscape is well-established. The main objective of the company in the coming years is to continue to sustain our current virtuous cycle of expansion and reinvestment in research and development. Constant innovation is integral to who we are; it was the basis for our past and present successes, and is the key to our future.
Chiesi’s people are at the heart of this vision, embodying our values and driving innovation through the contribution of bold new ideas to our development programmes.
In the coming year we will continue our pioneering work with cell and gene therapies, as well as on other molecular entity drugs which we have in the pipeline. These drugs hold enormous promise for addressing many hitherto challenging or untreatable conditions, and we are committed to realizing their potential”.
Headquartered in Parma, Italy Chiesi Farmaceutici is an international research-focused Healthcare group, with over 80 years of experience in the pharmaceutical industry. Chiesi researches, develops and markets innovative drugs in the the respiratory therapeutics, specialist medicine and rare diseases areas.
Its R&D centers in Parma (Italy), Paris (France), Cary (USA), Chippenham (UK) and the R&D team of the acquired Danish company Zymenex, integrate their efforts to advance Chiesi's pre-clinical, clinical and registration programs. Chiesi employs over 4,500 people, 560 of whom are solely dedicated to Research and Development activities.